Device Trial Radar · NCT03395522
Study to Assess the Efficacy of the iTind in Subjects With Symptomatic BPH
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
149
Actual
Start
Feb 18, 2018
Primary completion
Jun 18, 2023
Study completion Apr 25, 2025
Sponsor
- Lead sponsor
- Medi-Tate Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 10, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A total of up to 200 Symptomatic BPH subjects subjects will be enrolled into the study. Study duration will be 12 months post implantation with a follow-up visits at Year 2 and Year 3.
Conditions
- BPH
Interventions
iTindDevice
device implanted for 5-7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- IPSS (International Prostate Symptoms Score) Responders RateTime frame: at Month 6 Visit
Locations
12 sites in 6 countries. Site status is shown where the registry gives one.
Sydney Adventist Hospital Clinical School of the University of Sydney
Sydney, Australia
Hospital Center University De Bordeaux
Bordeaux, France
Hôpital Cochin
Paris, France
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.